Vertex Pharmaceuticals Share Price Today
(NASDAQ: VRTX)

Name: Vertex Pharmaceuticals Share Price Today (NASDAQ: VRTX) - Vertex Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Vertex Pharmaceuticals share price is $492.69 & ₹42,100.85 as on 28 Mar 2025, 09.30 hrs IST

$492.69

▲

-9.86

(-1.96%)

Market is closed - opens 7 PM, 31 Mar 2025

View live Vertex Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Vertex Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Vertex Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Vertex Pharmaceuticals share price movements

Today's Low: $491.79
Today's High: $504.33
$492.69
0.18%
Downside
Day's Volatility :2.49%
Upside
2.31%
52 Weeks Low: $377.85
52 Weeks High: $519.88
$492.69
23.31%
Downside
52 Weeks Volatility :27.32%
Upside
5.23%

Vertex Pharmaceuticals (VRTX) Returns

Period	Vertex Pharmaceuticals Incorporated	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	23.37%	4.0%	-12.2%
6 Months	5.94%	-5.6%	-4.4%
1 Year	17.17%	-2.2%	5.8%
3 Years	92.07%	4.7%	18.5%

Vertex Pharmaceuticals (VRTX) Key Statistics

in dollars & INR

Previous Close	$502.55
Open	$504.79
Today's High	$504.325
Today's Low	$491.79
Market Capitalization	$126.5B
Today's Volume	$1.3M
52 Week High	$519.88
52 Week Low	$377.85
Revenue TTM	$11.0B
EBITDA	$4.8B
Earnings Per Share (EPS)	$-2.07
Profit Margin	-4.86%
Quarterly Earnings Growth YOY	-0.06%
Return On Equity TTM	-3.15%

How to invest in Vertex Pharmaceuticals Stock (VRTX) from India?

It is very easy for Indian residents to invest directly in Vertex Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vertex Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vertex Pharmaceuticals or VRTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vertex Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vertex Pharmaceuticals shares which would translate to 0.002 fractional shares of Vertex Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Vertex Pharmaceuticals, in just a few clicks!

Returns in Vertex Pharmaceuticals (VRTX) for Indian investors in Rupees

The Vertex Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Vertex Pharmaceuticals investment value today

Current value as on today

₹1,19,711

Returns

₹19,711

(+19.71%)

Returns from Vertex Pharmaceuticals Stock

₹17,173 (+17.17%)

Dollar Returns

₹2,538 (+2.54%)

Indian investors sentiment towards Vertex Pharmaceuticals (VRTX)

-6.67%

Period: Feb 26, 2025 to Mar 28, 2025. Change in 30 Days versus previous period

Investment in Vertex Pharmaceuticals Shares from India has dropped by -6.67% over the past 30 days, indicating reduced transactional activity.

-39%

Period: Feb 26, 2025 to Mar 28, 2025. Change in 30 Days versus previous period

Search interest for Vertex Pharmaceuticals Stock from India on INDmoney has decreased by -39% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Vertex Pharmaceuticals Stock (VRTX Ticker)

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	2222	30.22	0.24%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	3333	0.00	0.79%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	383	14.65	1.06%

Global Institutional Holdings in Vertex Pharmaceuticals

Capital World Investors
11.03%
Vanguard Group Inc
9.06%
BlackRock Inc
8.50%
State Street Corp
4.67%
Capital Research Global Investors
4.06%
FMR Inc
3.59%

Analyst Recommendation on Vertex Pharmaceuticals

Buy

68%Buy

26%Hold

5%Sell

Based on 38 Wall street analysts offering stock ratings for Vertex Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 38 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Vertex Pharmaceuticals Stock (VRTX)

What analysts predicted

Upside of 0.91%

Target:

$497.19

Current:

$492.69

Insights on Vertex Pharmaceuticals Stock (Ticker Symbol: VRTX)

Price Movement
In the last 3 months, VRTX stock has moved up by 20.5%
Increasing Revenue
Vertex Pharmaceuticals Incorporated has demonstrated positive revenue growth over the last three quarters. Their revenue has increased from $2.63 billion to $2.91 billion, with an average increase of 4.9% each quarter.
Decreasing Net Profit
Vertex Pharmaceuticals Incorporated has experienced a decline in net profit over the last two quarters. The net profit decreased from $1.04 billion to $913 million, representing an average decrease of 12.7% each quarter.
VRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 79.6% return, outperforming this stock by 61.7%
Price to Sales
Vertex Pharmaceuticals Incorporated has a Price-to-Sales Ratio of 11.5, meaning that investors are willing to pay $11.5 for every $1 of sales the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a higher Price-to-Sales Ratio of 15.2, indicating that investors value Alnylam's sales more than Vertex's sales.

Vertex Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Vertex Pharmaceuticals (VRTX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vertex Pharmaceuticals Incorporated	3.83%	5.94%	17.17%	92.07%	112.44%
Regeneron Pharmaceuticals, Inc.	-9.31%	-39.37%	-34.25%	-7.95%	34.75%
Beone Medicines Ltd	-3.95%	19.1%	67.93%	29.8%	113.25%
Alnylam Pharmaceuticals, Inc.	13.23%	-2.39%	75.09%	62.47%	146.68%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vertex Pharmaceuticals Incorporated	32.84	NA	1.4	18.06	-0.03	0.13	NA	63.87
Regeneron Pharmaceuticals, Inc.	16.61	16.61	0.95	42.62	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.45	-0.19	-0.06	NA	31.22
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.83	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vertex Pharmaceuticals Incorporated	Buy	$126.5B	112.44%	32.84	-4.86%
Regeneron Pharmaceuticals, Inc.	Buy	$69.7B	34.75%	16.61	31.07%
Beone Medicines Ltd	NA	$30.6B	113.25%	NA	-16.92%
Alnylam Pharmaceuticals, Inc.	Buy	$34.7B	146.68%	NA	-12.37%

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Organization	Vertex Pharmaceuticals
Employees	6100
CEO	Dr. Reshma Kewalramani FASN, M.D.
Industry	Health Technology

Management People of Vertex Pharmaceuticals

Name	Title
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director
Mr. Charles F. Wagner Jr.	Executive VP & CFO
Mr. Stuart A. Arbuckle B.Sc.	Executive VP & COO
Dr. David M. Altshuler M.D., Ph.D.	Executive VP & Chief Scientific Officer
Ms. Kristen C. Ambrose CPA	Senior VP & Chief Accounting Officer
Ms. Susie Lisa C.F.A.	Senior Vice President of Investor Relations
Mr. Jonathan Biller J.D.	Executive VP & Chief Legal Officer
Ms. Nina Devlin	Senior VP & Chief Communications Officer
Ms. Stephanie Franklin	Senior VP & Chief Human Resources Officer

Important FAQs about investing in VRTX Stock from India :

What is Vertex Pharmaceuticals share price today?

Vertex Pharmaceuticals share price today stands at $492.69, Open: $504.79 ; Previous Close: $502.55 ; High: $504.33 ; Low: $491.79 ; 52 Week High: $519.88 ; 52 Week Low: $377.85.

The stock opens at $504.79, after a previous close of $502.55. The stock reached a daily high of $504.33 and a low of $491.79, with a 52-week high of $519.88 and a 52-week low of $377.85.

Can Indians buy Vertex Pharmaceuticals shares?

Yes, Indians can invest in the Vertex Pharmaceuticals (VRTX) from India.

With INDmoney, you can buy Vertex Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Vertex Pharmaceuticals at zero transaction cost.

How can I buy Vertex Pharmaceuticals shares from India?

It is very easy to buy Vertex Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vertex Pharmaceuticals (VRTX) be purchased?

Yes, you can buy fractional shares of Vertex Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Vertex Pharmaceuticals stocks?

To start investing in Vertex Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.